Who
Christopher James Frankenfield
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Xilio Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $16K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Aug 2023
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,5227,030 at $0.6432 | filing |
| 2 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,4997,030 at $0.64 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Code M | —19,375 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,375 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,375 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Code M | —19,375 | filing |
| 31 Dec 2025filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —668,789 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —668,789 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —925,000 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —155,090 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,090 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,786 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,786 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,296 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,296 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —117,000 | filing |
News
No headline names them, or the companies they trade most, lately.